Navigation Links
Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
Date:9/4/2012

NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that the company has named Richard A. Franco, Sr. to its Board of Directors.

Richard A. Franco is the President of the Richard's Group, Ltd., a healthcare advisory firm and cofounder of LipoScience, Inc. He has over 35 years of executive and leadership experience in the healthcare industry. Since January 2009, Mr. Franco had served as Chairman, President and Chief Executive Officer of DARA Pharmaceuticals, Inc. Prior to that, he served in several senior executive capacities at Glaxo, Inc., DARA, LipoScience, Inc., Trimeris Inc. with over 16 years with Eli Lilly and Company. He is currently on the boards of Metropolitan Health Networks, Inc., and Research Triangle Chapter of the National Association of Corporate Directors (NACD) and served on the boards of Salix Pharmaceuticals, as well as TriPath Imaging, Inc., NeoMatrix, Inc., Tranzyme, Inc., EntreMed, Inc., Amarillo Biosciences, and the Wake County United Way. He received a B.S. in Pharmacy from St. John's University and has completed executive programs at the Wharton School of the University of Pennsylvania, Duke University Fuqua School of Business, the School of Business at the University of Michigan, Tuck School of Business at Dartmouth College and the Kellogg School of Management at Northwestern University.

"Richard brings a distinguished career and important skill sets to our Board of Directors and we welcome his insights as we mature as a public company," said John Steel, Chairman and CEO of Islet Sciences. "Richard's significant experience and success both operationally and as a Director is a perfect fit for our company as Islet Sciences works toward a new treatment modality for diabetes. We look forward to Richard's counsel and expertise in driving the success of Islet Sciences forward."  

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.  The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace. www.isletsciences.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson
ProActive Capital Group
(646) 863-6893
jramson@proactivecrg.com


'/>"/>
SOURCE Islet Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
2. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
3. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
4. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
5. Life Technologies to Present at UBS Global Life Sciences Conference
6. Three Hertz Foundation Fellows Receive Presidential Honors; Leaders in Applied Physical, Biological and Engineering Sciences
7. Life Sciences Venture Capital Funding Shrinks for Fourth Straight Quarter According to the MoneyTree Report
8. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
9. NSBRI Renews Space Life Sciences Graduate Programs at MIT, Texas A&M
10. Neurocrine Biosciences Reports Second Quarter 2012 Results
11. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... PA (PRWEB) , ... May 19, 2017 , ... ... its QED Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, and ... New Jersey and Delaware, are encouraged to submit proposals. QED, now in its ...
(Date:5/18/2017)... ... 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point Partners II ... grow. CSM has doubled in size over the past six months with the ... , Roger Gasper joins CSM as Chief Financial Officer. Roger has over 25 ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... in medical device compliance and commercialization, has just released version 9.0 of the ... into this latest version of Cockpit,” says David Cronin, CEO of Cognition. “We’re ...
(Date:5/18/2017)... ... May 17, 2017 , ... G-CON Manufacturing, Inc., the ... Officer, Maik Jornitz, was recognized as a Top 10 Industry Influencer on The ... “involved in bettering the pharma industry and bringing life-changing medicines to market” across ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/20/2017)... March 20, 2017 PMD Healthcare announces the ... and Wellness Management System (WMS), a remote, real-time lung ... 2010, PMD Healthcare is a Medical Device, Digital Health, ... dedicated to creating innovative solutions that empower people to ... intent focus, PMD developed the first ever personal spirometer, ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):